<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.jem.org">
<title>Latest Articles</title>
<link>http://www.jem.org</link>
<description>JEM RSS Feed -- Latest Articles</description>
<prism:eIssn>1540-9538</prism:eIssn>
<prism:publicationName>Journal of Experimental Medicine</prism:publicationName>
<prism:issn>0022-1007</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20072646v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20071990v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20071987v2?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20080281v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20080178v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20072682v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20072683v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20072390v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20072102v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.2058iti2v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20072446v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20072448v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20071427v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.20071463v1?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/jem.2058iti1v1?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://www.jem.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://www.jem.org/icons/banner/title.gif">
<title>Journal of Experimental Medicine</title>
<url>http://www.jem.org/icons/banner/title.gif</url>
<link>http://www.jem.org</link>
</image>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20072646v1?rss=1">
<title><![CDATA[Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20072646v1?rss=1</link>
<description><![CDATA[<p>The <I>Sigirr</I> gene (also known as Tir8) encodes for an orphan receptor of the Toll-like receptor (TLR)/interleukin 1 receptor family that inhibits TLR-mediated pathogen recognition in dendritic cells. Here, we show that <I>Sigirr</I> also inhibits the activation of dendritic cells and B cells upon exposure to RNA and DNA lupus autoantigens. To evaluate the functional role of <I>Sigirr</I> in the pathogenesis of systemic lupus erythematosus (SLE), we generated <I>Sigirr</I>-deficient C57BL/6-lpr/lpr mice. These mice developed a progressive lymphoproliferative syndrome followed by severe autoimmune lung disease and lupus nephritis within 6 mo of age as compared with the minor abnormalities observed in C57BL/6-lpr/lpr mice. Lack of <I>Sigirr</I> was associated with enhanced activation of dendritic cells and increased expression of multiple proinflammatory and antiapoptotic mediators. In the absence of <I>Sigirr</I>, CD4 T cell numbers were increased and CD4<sup>+</sup>CD25<sup>+</sup> T cell numbers were reduced. Furthermore, lack of <I>Sigirr</I> enhanced the activation and proliferation of B cells, including the production of autoantibodies against multiple nuclear lupus autoantigens. These data identify <I>Sigirr</I> as a novel SLE susceptibility gene in mice.</p>]]></description>
<dc:creator><![CDATA[Lech, M., Kulkarni, O. P., Pfeiffer, S., Savarese, E., Krug, A., Garlanda, C., Mantovani, A., Anders, H.-J.]]></dc:creator>
<dc:date>2008-07-21</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072646</dc:identifier>
<dc:title><![CDATA[Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-21</prism:publicationDate>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20071990v1?rss=1">
<title><![CDATA[TLR4-induced IFN-{gamma} production increases TLR2 sensitivity and drives Gram-negative sepsis in mice]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20071990v1?rss=1</link>
<description><![CDATA[<p>Gram-negative bacterial infection is a major cause of sepsis and septic shock. An important inducer of inflammation underlying both syndromes is the cellular recognition of bacterial products through pattern recognition receptors (PRRs), including Toll-like receptors (TLRs). We identified a novel antagonistic mAb (named 1A6) that recognizes the extracellular portion of the TLR4&ndash;MD-2 complex. If applied to mice before infection with clinical isolates of <I>Salmonella enterica</I> or <I>Escherichia coli</I> and subsequent antibiotic therapy, 1A6 prevented otherwise fatal shock, whereas application of 1A6 after infection was ineffective. In contrast, coapplication of 1A6 and an anti-TLR2 mAb up to 4 h after infection with Gram-negative bacteria, in combination with the start of antibiotic therapy (mimicking clinical conditions), provided robust protection. Consistent with our findings in mice, dual blockade of TLR2 and TLR4 inhibited TNF- release from human peripheral blood mononuclear cells upon Gram-negative bacterial infection/antibiotic therapy. Both murine splenocytes and human PBMCs released IFN- in a TLR4-dependent manner, leading to enhanced surface TLR2 expression and sensitivity for TLR2 ligands. Our results implicate TLR2 as an important, TLR4-driven sensor of Gram-negative bacterial infection and provide a rationale for blockade of both TLRs, in addition to antibiotic therapy for the treatment of Gram-negative bacterial infection.</p>]]></description>
<dc:creator><![CDATA[Spiller, S., Elson, G., Ferstl, R., Dreher, S., Mueller, T., Freudenberg, M., Daubeuf, B., Wagner, H., Kirschning, C. J.]]></dc:creator>
<dc:date>2008-07-21</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071990</dc:identifier>
<dc:title><![CDATA[TLR4-induced IFN-{gamma} production increases TLR2 sensitivity and drives Gram-negative sepsis in mice]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-21</prism:publicationDate>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20071987v2?rss=1">
<title><![CDATA[Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20071987v2?rss=1</link>
<description><![CDATA[<p>Germline mutations may cause human disease by various mechanisms. Missense and other in-frame mutations may be deleterious because the mutant proteins are not correctly targeted, do not function correctly, or both. We studied a child with mycobacterial disease caused by homozygosity for a novel in-frame microinsertion in <I>IFNGR2</I>. In cells transfected with the mutant allele, most of the interferon  receptor 2 (IFN-R2) protein was retained within the cell, and that expressed on the cell surface had an abnormally high molecular weight (MW). The misfolding mutation was not gain-of-glycosylation, as it created no new N-glycosylation site. The mutant <I>IFNGR2</I> allele was null, as the patient's cells did not respond to IFN-. Based on the well-established relationship between protein N-glycosylation and protein quality control processes, we tested 29 compounds affecting maturation by N-glycosylation in the secretory pathway. Remarkably, up to 13 of these compounds reduced the MW of surface-expressed mutant IFN-R2 molecules and restored cellular responsiveness to IFN-. Modifiers of N-glycosylation may therefore complement human cells carrying in-frame and misfolding, but not necessarily gain-of-glycosylation, mutations in genes encoding proteins subject to trafficking via the secretory pathway. Some of these compounds are available for clinical use, paving the way for clinical trials of chemical complementation for various human genetic traits.</p>]]></description>
<dc:creator><![CDATA[Vogt, G., Bustamante, J., Chapgier, A., Feinberg, J., Boisson Dupuis, S., Picard, C., Mahlaoui, N., Gineau, L., Alcais, A., Lamaze, C., Puck, J. M., de Saint Basile, G., Djambas Khayat, C., Mikhael, R., Casanova, J.-L.]]></dc:creator>
<dc:date>2008-07-18</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071987</dc:identifier>
<dc:title><![CDATA[Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-18</prism:publicationDate>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20080281v1?rss=1">
<title><![CDATA[Immune-driven recombination and loss of control after HIV superinfection]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20080281v1?rss=1</link>
<description><![CDATA[
<p>After acute HIV infection, CD8<sup>+</sup> T cells are able to control viral replication to a set point. This control is often lost after superinfection, although the mechanism behind this remains unclear. In this study, we illustrate in an HLA-B27<sup>+</sup> subject that loss of viral control after HIV superinfection coincides with rapid recombination events within two narrow regions of Gag and Env. Screening for CD8<sup>+</sup> T cell responses revealed that each of these recombination sites (~50 aa) encompassed distinct regions containing two immunodominant CD8 epitopes (B27-KK10 in Gag and Cw1-CL9 in Env). Viral escape and the subsequent development of variant-specific de novo CD8<sup>+</sup> T cell responses against both epitopes were illustrative of the significant immune selection pressures exerted by both responses. Comprehensive analysis of the kinetics of CD8 responses and viral evolution indicated that the recombination events quickly facilitated viral escape from both dominant WT- and variant-specific responses. These data suggest that the ability of a superinfecting strain of HIV to overcome preexisting immune control may be related to its ability to rapidly recombine in critical regions under immune selection pressure. These data also support a role for cellular immune pressures in driving the selection of new recombinant forms of HIV.</p>
]]></description>
<dc:creator><![CDATA[Streeck, H., Li, B., Poon, A. F.Y., Schneidewind, A., Gladden, A. D., Power, K. A., Daskalakis, D., Bazner, S., Zuniga, R., Brander, C., Rosenberg, E. S., Frost, S. D.W., Altfeld, M., Allen, T. M.]]></dc:creator>
<dc:date>2008-07-14</dc:date>
<dc:identifier>info:doi/10.1084/jem.20080281</dc:identifier>
<dc:title><![CDATA[Immune-driven recombination and loss of control after HIV superinfection]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-14</prism:publicationDate>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20080178v1?rss=1">
<title><![CDATA[A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20080178v1?rss=1</link>
<description><![CDATA[
<p>Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by both neurological and systemic abnormalities. We examined the peripheral immune system and found widespread evidence of innate immune activation detectable in plasma throughout the course of HD. Interleukin 6 levels were increased in HD gene carriers with a mean of 16 years before the predicted onset of clinical symptoms. To our knowledge, this is the earliest plasma abnormality identified in HD. Monocytes from HD subjects expressed mutant huntingtin and were pathologically hyperactive in response to stimulation, suggesting that the mutant protein triggers a cell-autonomous immune activation. A similar pattern was seen in macrophages and microglia from HD mouse models, and the cerebrospinal fluid and striatum of HD patients exhibited abnormal immune activation, suggesting that immune dysfunction plays a role in brain pathology. Collectively, our data suggest parallel central nervous system and peripheral pathogenic pathways of immune activation in HD.</p>
]]></description>
<dc:creator><![CDATA[Bjorkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., Magnusson, A., Woodman, B., Landles, C., Pouladi, M. A., Hayden, M. R., Khalili-Shirazi, A., Lowdell, M. W., Brundin, P., Bates, G. P., Leavitt, B. R., Moller, T., Tabrizi, S. J.]]></dc:creator>
<dc:date>2008-07-14</dc:date>
<dc:identifier>info:doi/10.1084/jem.20080178</dc:identifier>
<dc:title><![CDATA[A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-14</prism:publicationDate>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20072682v1?rss=1">
<title><![CDATA[Discriminating gene expression profiles of memory B cell subpopulations]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20072682v1?rss=1</link>
<description><![CDATA[
<p>Morphologically and functionally distinct subpopulations of human memory B (B<SUB>Mem</SUB>) cells are identifiable by either their expression of CD27 or Fc receptor&ndash;like 4 (FCRL4), an immunoglobulin domain containing a receptor with strong inhibitory potential. We have conducted comparative transcriptome and proteome analyses of FCRL4<sup>+</sup> and FCRL4<sup>&ndash;</sup> B<SUB>Mem</SUB> cells and found that these two subsets have very distinctive expression profiles for genes encoding transcription factors, cell-surface proteins, intracellular signaling molecules, and modifiers of the cell-cycle status. Among the differentially expressed transcription factors, runt-related transcription factor 1 (RUNX1) transcript levels were up-regulated in FCRL4<sup>&ndash;</sup> cells, whereas RUNX2 transcripts were preferentially detected in FCRL4<sup>+</sup> cells. In vitro evidence for FCRL4 promoter responsiveness and in vivo promoter occupancy suggested that RUNX transcription factors are involved in the generation of these B<SUB>Mem</SUB> cell subpopulations. A distinctive signature profile was defined for the FCRL4<sup>+</sup> B<SUB>Mem</SUB> cells by their expression of CD11c, receptor activator for nuclear factor B ligand, and FAS cell-surface proteins, in combination with increased levels of <I>SOX5</I>, <I>RUNX2</I>, <I>DLL1</I>, and <I>AICDA</I> expression. We conclude that this recently identified subpopulation of B<SUB>Mem</SUB> cells, which normally resides in epithelial tissue-based niches, may serve a unique role in mucosal defense and, conversely, as a target for neoplastic transformation events.</p>
]]></description>
<dc:creator><![CDATA[Ehrhardt, G. R.A., Hijikata, A., Kitamura, H., Ohara, O., Wang, J.-Y., Cooper, M. D.]]></dc:creator>
<dc:date>2008-07-14</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072682</dc:identifier>
<dc:title><![CDATA[Discriminating gene expression profiles of memory B cell subpopulations]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-14</prism:publicationDate>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20072683v1?rss=1">
<title><![CDATA[Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20072683v1?rss=1</link>
<description><![CDATA[
<p>Human immunodeficiency virus (HIV) disease leads to impaired B cell and antibody responses through mechanisms that remain poorly defined. A unique memory B cell subpopulation (CD20<sup>hi</sup>/CD27<sup>lo</sup>/CD21<sup>lo</sup>) in human tonsillar tissues was recently defined by the expression of the inhibitory receptor Fc-receptor-like-4 (FCRL4). In this study, we describe a similar B cell subpopulation in the blood of HIV-viremic individuals. FCRL4 expression was increased on B cells of HIV-viremic compared with HIV-aviremic and HIV-negative individuals. It was enriched on B cells with a tissuelike memory phenotype (CD20<sup>hi</sup>/CD27<sup>&ndash;</sup>/CD21<sup>lo</sup>) when compared with B cells with a classical memory (CD27<sup>+</sup>) or naive (CD27<sup>&ndash;</sup>/CD21<sup>hi</sup>) B cell phenotype. Tissuelike memory B cells expressed patterns of homing and inhibitory receptors similar to those described for antigen-specific T cell exhaustion. The tissuelike memory B cells proliferated poorly in response to B cell stimuli, which is consistent with high-level expression of multiple inhibitory receptors. Immunoglobulin diversities and replication histories were lower in tissuelike, compared with classical, memory B cells, which is consistent with premature exhaustion. Strikingly, HIV-specific responses were enriched in these exhausted tissuelike memory B cells, whereas total immunoglobulin and influenza-specific responses were enriched in classical memory B cells. These data suggest that HIV-associated premature exhaustion of B cells may contribute to poor antibody responses against HIV in infected individuals.</p>
]]></description>
<dc:creator><![CDATA[Moir, S., Ho, J., Malaspina, A., Wang, W., DiPoto, A. C., O'Shea, M. A., Roby, G., Kottilil, S., Arthos, J., Proschan, M. A., Chun, T.-W., Fauci, A. S.]]></dc:creator>
<dc:date>2008-07-14</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072683</dc:identifier>
<dc:title><![CDATA[Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-14</prism:publicationDate>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20072390v1?rss=1">
<title><![CDATA[Avidity maturation of memory CD8 T cells is limited by self-antigen expression]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20072390v1?rss=1</link>
<description><![CDATA[
<p>Immune tolerance to self-antigens is a complex process that utilizes multiple mechanisms working in concert to maintain homeostasis and prevent autoimmunity. We developed a system that revealed a population of self-specific CD8 T cells within the endogenous T cell repertoire. Immunization of ovalbumin (OVA)-expressing transgenic mice with recombinant viruses expressing OVA-peptide variants induced self-reactive T cells in vivo that matured into memory T cells able to respond to secondary infection. However, whereas the avidity of memory cells in normal mice increased dramatically with repeated immunizations, avidity maturation was limited for self-specific CD8 T cells. Despite decreased avidity, such memory cells afforded protection against infection, but did not induce overt autoimmunity. Further, up-regulation of self-antigen expression in dendritic cells using an inducible system promoted programmed death-1 expression, but not clonal expansion of preexisting memory cells. Thus, the self-reactive T cell repertoire is controlled by overlapping mechanisms influenced by antigen dose.</p>
]]></description>
<dc:creator><![CDATA[Turner, M. J., Jellison, E. R., Lingenheld, E. G., Puddington, L., Lefrancois, L.]]></dc:creator>
<dc:date>2008-07-14</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072390</dc:identifier>
<dc:title><![CDATA[Avidity maturation of memory CD8 T cells is limited by self-antigen expression]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-14</prism:publicationDate>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20072102v1?rss=1">
<title><![CDATA[Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20072102v1?rss=1</link>
<description><![CDATA[
<p>In mantle cell lymphoma (MCL) and some cases of multiple myeloma (MM), cyclin D1 expression is deregulated by chromosome translocations involving the immunoglobulin heavy chain (IgH) locus. To evaluate the mechanisms responsible, gene targeting was used to study long-distance gene regulation. Remarkably, these targeted cell lines lost the translocated chromosome (t(11;14)). In these MCL and MM cells, the nonrearranged <I>cyclin D1</I> (<I>CCND1</I>) locus reverts from CpG hypomethylated to hypermethylated. Reintroduction of the translocated chromosome induced a loss of methylation at the unrearranged <I>CCND1</I> locus, providing evidence of a transallelic regulatory effect. In these cell lines and primary MCL patient samples, the <I>CCND1</I> loci are packaged in chromatin-containing CCCTC binding factor (CTCF) and nucleophosmin (NPM) at the nucleolus. We show that CTCF and NPM are bound at the IgH 3' regulatory elements only in the t(11;14) MCL cell lines. Furthermore, NPM short hairpin RNA produces a specific growth arrest in these cells. Our data demonstrate transvection in human cancer and suggest a functional role for CTCF and NPM.</p>
]]></description>
<dc:creator><![CDATA[Liu, H., Huang, J., Wang, J., Jiang, S., Bailey, A. S., Goldman, D. C., Welcker, M., Bedell, V., Slovak, M. L., Clurman, B., Thayer, M., Fleming, W. H., Epner, E.]]></dc:creator>
<dc:date>2008-07-14</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072102</dc:identifier>
<dc:title><![CDATA[Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-14</prism:publicationDate>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.2058iti2v1?rss=1">
<title><![CDATA[HIV switches to escape]]></title>
<link>http://www.jem.org/cgi/content/short/jem.2058iti2v1?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-07-14</dc:date>
<dc:identifier>info:doi/10.1084/jem.2058iti2</dc:identifier>
<dc:title><![CDATA[HIV switches to escape]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-14</prism:publicationDate>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20072446v1?rss=1">
<title><![CDATA[Continuous engagement of a self-specific activation receptor induces NK cell tolerance]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20072446v1?rss=1</link>
<description><![CDATA[
<p>Natural killer (NK) cell tolerance mechanisms are incompletely understood. One possibility is that they possess self-specific activation receptors that result in hyporesponsiveness unless modulated by self&ndash;major histocompatability complex (MHC)&ndash;specific inhibitory receptors. As putative self-specific activation receptors have not been well characterized, we studied a transgenic C57BL/6 mouse that ubiquitously expresses m157 (m157-Tg), which is the murine cytomegalovirus (MCMV)&ndash;encoded ligand for the Ly49H NK cell activation receptor. The transgenic mice were more susceptible to MCMV infection and were unable to reject m157-Tg bone marrow, suggesting defects in Ly49H<sup>+</sup> NK cells. There was a reversible hyporesponsiveness of Ly49H<sup>+</sup> NK cells that extended to Ly49H-independent stimuli. Continuous Ly49H&ndash;m157 interaction was necessary for the functional defects. Interestingly, functional defects occurred when mature wild-type NK cells were adoptively transferred to m157-Tg mice, suggesting that mature NK cells may acquire hyporesponsiveness. Importantly, NK cell tolerance caused by Ly49H&ndash;m157 interaction was similar in NK cells regardless of expression of Ly49C, an inhibitory receptor specific for a self-MHC allele in C57BL/6 mice. Thus, engagement of self-specific activation receptors in vivo induces an NK cell tolerance effect that is not affected by self-MHC&ndash;specific inhibitory receptors.</p>
]]></description>
<dc:creator><![CDATA[Tripathy, S. K., Keyel, P. A., Yang, L., Pingel, J. T., Cheng, T. P., Schneeberger, A., Yokoyama, W. M.]]></dc:creator>
<dc:date>2008-07-07</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072446</dc:identifier>
<dc:title><![CDATA[Continuous engagement of a self-specific activation receptor induces NK cell tolerance]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-07</prism:publicationDate>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20072448v1?rss=1">
<title><![CDATA[Tolerance of NK cells encountering their viral ligand during development]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20072448v1?rss=1</link>
<description><![CDATA[
<p>During development, T and B cells encountering their cognate ligands via antigen-specific receptors are deleted or rendered anergic. Like T and B cells, natural killer (NK) cells express certain receptors, such as Ly49H, associated with immunoreceptor tyrosine-based activation motif&ndash;bearing adaptor proteins that transmit activating signals through Syk family kinases. Ly49H binds with high affinity to a mouse cytomegalovirus (MCMV)&ndash;encoded glycoprotein, m157, but does not recognize self-antigens. For comparison with the behavior of immature T and B cells exposed to foreign antigens, we addressed the fate of Ly49H<sup>+</sup> NK cells that encountered their viral ligand during development by retroviral transduction of bone marrow stem cells with m157. In chimeric mice expressing m157, we observed a reduction in Ly49H<sup>+</sup> NK cells in multiple tissues and less Ly49H on the cell surface. NK cells exposed to m157 during development appeared less mature, produced less interferon  when stimulated through Ly49H, and were unable to kill m157-bearing target cells. After MCMV infection, these NK cells were severely impaired in their ability to proliferate. Thus, if immature NK cells encounter ligands for their activating receptors, regulatory mechanisms exist to keep these cells in an unresponsive state.</p>
]]></description>
<dc:creator><![CDATA[Sun, J. C., Lanier, L. L.]]></dc:creator>
<dc:date>2008-07-07</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072448</dc:identifier>
<dc:title><![CDATA[Tolerance of NK cells encountering their viral ligand during development]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-07</prism:publicationDate>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20071427v1?rss=1">
<title><![CDATA[Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20071427v1?rss=1</link>
<description><![CDATA[
<p>Thrombin, acting through a family of protease-activated receptors (PARs), is known to amplify inflammatory responses, but the in vivo importance of PARs in inflammation is not fully appreciated. In a mouse heart-to-rat transplant model, where it is possible to distinguish graft (mouse) from systemic (rat) chemokines, we show that donor PAR-1 is required to generate the local monocyte chemoattractant protein (MCP)-1 needed to recruit rat natural killer cells and macrophages into the hearts. We have confirmed the importance of this mechanism in a second model of thioglycollate-induced peritonitis and also show that PAR-1 is important for the production of MCP-3 and MCP-5. Despite the presence of multiple other mediators capable of stimulating chemokine production in these models, these data provide the first evidence that thrombin and PAR activation are required in vivo to initiate inflammatory cell recruitment.</p>
]]></description>
<dc:creator><![CDATA[Chen, D., Carpenter, A., Abrahams, J., Chambers, R. C., Lechler, R. I., McVey, J. H., Dorling, A.]]></dc:creator>
<dc:date>2008-07-07</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071427</dc:identifier>
<dc:title><![CDATA[Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-07</prism:publicationDate>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.20071463v1?rss=1">
<title><![CDATA[Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model]]></title>
<link>http://www.jem.org/cgi/content/short/jem.20071463v1?rss=1</link>
<description><![CDATA[
<p>Humans express a unique subset of high-density lipoproteins (HDLs) called trypanosome lytic factors (TLFs) that kill many <I>Trypanosoma</I> parasite species. The proteins apolipoprotein (apo) A-I, apoL-I, and haptoglobin-related protein, which are involved in TLF structure and function, were expressed through the introduction of transgenes in mice to explore their physiological roles in vivo. Transgenic expression of human apolipoprotein L-I alone conferred trypanolytic activity in vivo. Coexpression of human apolipoprotein A-I and haptoglobin-related protein (Hpr) had an effect on the integration of apolipoprotein L-I into HDL, and both proteins were required to increase the specific activity of TLF, which was measurable in vitro. Unexpectedly, truncated apolipoprotein L-I devoid of the serum resistance gene interacting domain, which was previously shown to kill human infective trypanosomes, was not trypanolytic in transgenic mice despite being coexpressed with human apolipoprotein A-I and Hpr and incorporated into HDLs. We conclude that all three human apolipoproteins act cooperatively to achieve maximal killing capacity and that truncated apolipoprotein L-I does not function in transgenic animals.</p>
]]></description>
<dc:creator><![CDATA[Molina-Portela, M. P., Samanovic, M., Raper, J.]]></dc:creator>
<dc:date>2008-07-07</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071463</dc:identifier>
<dc:title><![CDATA[Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-07</prism:publicationDate>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/jem.2058iti1v1?rss=1">
<title><![CDATA[Triple punch against trypanosomes]]></title>
<link>http://www.jem.org/cgi/content/short/jem.2058iti1v1?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-07-07</dc:date>
<dc:identifier>info:doi/10.1084/jem.2058iti1</dc:identifier>
<dc:title><![CDATA[Triple punch against trypanosomes]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:publicationDate>2008-07-07</prism:publicationDate>
<prism:section>In This Issue</prism:section>
</item>

</rdf:RDF>